

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Pridopidine for treating Huntington's disease ID6525

Provisional Stakeholder List

| Provisional Consultees | Provisional Commentators (no right to submit or appeal) |
|--|--|
| <p><u>Company</u></p> <ul style="list-style-type: none"> • Prilenia (pridopidine) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action on Pain • Alzheimer's Research UK • Alzheimer's Society • Association of Mental Health Providers • Brain and Spine Foundation • Brain Charity • Depression UK • Genetic Alliance UK • Huntington's Disease Association • Mental Health Foundation • MIND • Neurological Alliance • Pain Concern • Pain UK • South Asian Health Foundation • Specialised Healthcare Alliance • United Response <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> • Association of British Neurologists • Association of Genetic Nurses & Counsellors • British Association of Behavioural and Cognitive Psychotherapies • British Association of Social Workers • British Geriatrics Society • British Neuropathological Society • British Neuropsychiatry Association • British Pain Society • British Psychoanalytic Council • British Psychological Society | <p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health - Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Confederation • NHS Wales Joint Commissioning Committee • Scottish Medicines Consortium • Welsh Government <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • None <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Brain Research UK • Campbell Collaboration Social Welfare Group • Genomics England • Huntington's Disease Centre Cardiff • Institute of Neurology • Institute of Psychiatry • MRC Clinical Trials Unit • National Institute for Health Research • Pain Relief Foundation <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health Wales |

| Provisional Consultees | Provisional Commentators (no right to submit or appeal) |
|--|---|
| <ul style="list-style-type: none"> British Society for Gene and Cell Therapy British Society for Genetic Medicine College of Mental Health Pharmacy Counsellors and Psychotherapists in Primary Care Dementia Action Alliance Health and Care Professions Council Mental Health Nurses Association National Neurosciences Advisory Group Neuromodulation Society of UK and Ireland Physiotherapy Pain Association Primary Care and Community Neurology Society Primary Care Mental Health Education Royal College of General Practitioners Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal College of Psychiatrists Royal Pharmaceutical Society Royal Society of Medicine UK Clinical Pharmacy Association UK Council for Psychotherapy <p><u>Others</u></p> <ul style="list-style-type: none"> Department of Health and Social Care Huntington's Disease Clinic, Guy's and St Thomas' NHS Foundation Trust Huntington's Disease Multidisciplinary Clinic, National Hospital for Neurology and Neurosurgery, University College London Huntington's Disease Multidisciplinary Clinic, St George's University Hospitals NHS Foundation Trust Neurogenetic Team, Manchester Centre for Genomic Medicine NHS England | <ul style="list-style-type: none"> UK Health Security Agency |

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.